Echelon Wealth Partners reiterated top pick status to Acasti Pharma (TSXV:ACST) and Antibe Therapeutics (TSXV:ATE).
Acasti is developing an omega-3-based therapeutic for the treatment of hyperglyceridemia. Analyst Doug Loe maintained his “speculative buy” rating and $4.00 price target for Acasti, whose stock closed at $2.86 on Jan. 8.
He also maintained his “speculative buy” rating and $1.40 price target for Antibe, which is developing a pipeline of non-addictive pain and inflammation therapeutics. The stock closed at 47 cents on Jan. 8.
